Skip to main content
    J

    Johnson & Johnson (JNJ)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $282.84
    -2.91 (-1.02%)

    Market Cap: $687.89B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Johnson & Johnson (JNJ) Financials: Revenue, Profit and Cash Flow

    Updated Oct 13, 2026. Financial statements from company filings, amounts in US dollars.

    Johnson & Johnson reported revenue of $94.19B for the fiscal year ended Dec 31, 2025, up 6.0% from the year before. That year, net income was $26.80B with a net margin of 28.5%, operating cash flow was $24.53B and free cash flow was $19.70B. The quarter ended Sep 30, 2026 had revenue of $25.40B and net income of $210.00M.

    Revenue and Margins

    The operating margin was 26.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $71.89B, a compound annual rate of 3.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$94.19B+6.0%67.9%26.8%28.5%
    Dec 2024$88.82B+4.3%69.1%23.4%15.8%
    Dec 2023$85.16B+6.5%68.8%24.9%41.3%
    Dec 2022$79.99B+1.6%69.3%24.9%22.4%
    Dec 2021$78.74B-4.7%70.3%25.2%26.5%
    Dec 2020$82.58B+0.6%65.6%23.6%17.8%
    Dec 2019$82.06B+0.6%66.4%24.1%18.4%
    Dec 2018$81.58B+6.7%66.8%24.3%18.8%
    Dec 2017$76.45B+6.3%66.7%23.8%1.7%
    Dec 2016$71.89BN/A69.7%28.3%23.0%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 90.5% from the year before. In the quarter ended Sep 2026, net income fell 95.9% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$94.19B$88.82B$85.16B$79.99B$78.74B$82.58B$82.06B$81.58B$76.45B$71.89B
    Cost of revenue$30.26B$27.47B$26.55B$24.60B$23.40B$28.43B$27.56B$27.09B$25.44B$21.79B
    Gross profit$63.94B$61.35B$58.61B$55.39B$55.34B$54.16B$54.50B$54.49B$51.01B$50.10B
    Research and development$14.75B$17.44B$15.40B$14.92B$15.18B$12.34B$12.24B$11.90B$11.00B$9.17B
    Operating income$25.29B$20.80B$21.21B$19.95B$19.83B$19.49B$19.81B$19.80B$18.18B$20.37B
    Net income$26.80B$14.07B$35.15B$17.94B$20.88B$14.71B$15.12B$15.30B$1.30B$16.54B
    EBITDA$40.00B$23.45B$22.06B$26.11B$26.70B$23.82B$24.30B$25.32B$23.86B$23.91B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$25.40B$25.31B$24.06B$24.56B$23.99B$23.74B$21.89B$22.52B$22.47B$22.45B$21.38B$21.39B
    Gross profit$17.30B$17.26B$15.96B$16.60B$16.69B$16.11B$14.54B$15.39B$15.51B$15.58B$14.87B$14.60B
    Operating income$5.84B$7.14B$6.33B$5.43B$7.03B$6.65B$6.18B$3.58B$5.04B$6.28B$5.91B$4.19B
    Net income$210.00M$5.53B$5.24B$5.12B$5.15B$5.54B$11.00B$3.43B$2.69B$4.69B$3.25B$4.05B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $47.93B exceeded cash and equivalents by $28.22B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$199.21B$180.10B$167.56B$187.38B$182.02B$174.89B$157.73B$152.95B$157.30B$141.21B
    Current assets$55.62B$55.89B$53.49B$55.29B$60.98B$51.24B$45.27B$46.03B$43.09B$65.03B
    Cash and equivalents$19.71B$24.11B$21.86B$12.89B$14.49B$13.98B$17.30B$18.11B$17.82B$18.97B
    Total liabilities$117.67B$108.61B$98.78B$110.57B$108.00B$111.62B$98.26B$93.20B$97.14B$70.79B
    Short-term debt$8.49B$5.98B$3.45B$12.76B$3.77B$2.63B$1.20B$2.80B$3.91B$4.68B
    Long-term debt$39.44B$30.65B$25.88B$26.89B$29.98B$32.63B$26.49B$27.68B$30.68B$22.44B
    Shareholder equity$81.54B$71.49B$68.77B$76.80B$74.02B$63.28B$59.47B$59.75B$60.16B$70.42B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$197.43B$201.06B$200.89B$199.21B$192.82B$193.39B$193.67B$180.10B$178.29B$181.09B$171.97B$167.56B
    Total liabilities$115.90B$116.09B$119.71B$117.67B$113.54B$114.92B$115.56B$108.61B$108.13B$109.55B$101.95B$98.78B
    Cash and equivalents$16.91B$20.42B$21.69B$19.71B$18.23B$18.58B$38.47B$24.11B$19.98B$24.88B$25.47B$21.86B
    Shareholder equity$81.53B$84.97B$81.19B$81.54B$79.28B$78.47B$78.11B$71.49B$70.16B$71.54B$70.02B$68.77B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 80.3% of operating cash flow. Dividends and share repurchases together came to 93.0% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$24.53B$24.27B$22.79B$21.19B$23.41B$23.54B$23.42B$22.20B$21.06B$18.77B
    Capital expenditures$4.83B$4.42B$4.54B$4.01B$3.65B$3.35B$3.50B$3.67B$3.28B$3.23B
    Free cash flow$19.70B$19.84B$18.25B$17.18B$19.76B$20.19B$19.92B$18.53B$17.78B$15.54B
    Dividends paid$12.38B$11.82B$11.77B$11.68B$11.03B$10.48B$9.92B$9.49B$8.94B$8.62B
    Share repurchases$5.95B$2.43B$5.05B$6.04B$3.46B$3.22B$6.75B$5.87B$6.36B$8.98B
    Investing cash flow-$23.59B-$18.60B$878.00M-$12.37B-$8.68B-$20.82B-$6.19B-$3.17B-$14.87B-$4.76B
    Financing cash flow-$5.54B-$3.13B-$15.82B-$8.87B-$14.05B-$6.12B-$18.02B-$18.51B-$7.67B-$8.55B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$7.72B$8.62B$2.51B$7.31B$9.17B$3.88B$4.17B$6.98B$7.99B$5.63B$3.66B$7.86B
    Capital expenditures$2.36B$1.32B$1.05B$1.45B$1.17B$1.41B$795.00M$362.00M$2.28B$976.00M$807.00M$1.59B
    Free cash flow$5.36B$7.29B$1.47B$5.86B$8.00B$2.47B$3.38B$6.62B$5.71B$4.66B$2.85B$6.27B
    Last 12 quarters

    Frequently Asked Questions About JNJ

    What is Johnson & Johnson's annual revenue?

    Johnson & Johnson reported revenue of $94.19B for the fiscal year ended Dec 31, 2025.

    How fast is Johnson & Johnson's revenue growing?

    Revenue was up 6.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.6%.

    Is Johnson & Johnson profitable?

    Yes. Johnson & Johnson reported net income of $26.80B for the fiscal year ended Dec 31, 2025, with a net margin of 28.5%.

    How much free cash flow does JNJ generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $24.53B minus capital expenditures of $4.83B produced free cash flow of $19.70B.

    How much debt does Johnson & Johnson have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $39.44B, short-term debt of $8.49B and cash and equivalents of $19.71B.